Clinical Trial Search

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants

Primary: Progression-free Survival — 9.2; 8.9 months

Primary: Overall Survival — 24.8 Months

Primary: Recurrence Free Survival — 15.6 months

Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants

Primary: Survival — 37; 31 participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Incidence of Dose Limiting Toxicites (DLTs) — 0; 1 Dose limiting Toxicities

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee — 19.4; 18.8 months — p=0.1824

Primary: Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity — 0 Participants

Primary: Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)

Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants

Primary: Overall Survival at 18 Months — 63 percentage of participants

Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants

Primary: Percentage of Patients Discharged by Post-operative Day 5 — 5; 28 Participants

Primary: Two-year Disease Free Survival. — 26.1 percentage of patients

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants